PHARMANIAGA ENALAPRIL TABLET 20MG

Kraj: Malezja

Język: angielski

Źródło: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Składnik aktywny:

ENALAPRIL MALEATE

Dostępny od:

PHARMANIAGA MANUFACTURING BERHAD

INN (International Nazwa):

ENALAPRIL MALEATE

Sztuk w opakowaniu:

250 Tablets; 100 Tablets; 30 Tablets; 10 Tablets

Wyprodukowano przez:

PHARMANIAGA MANUFACTURING BERHAD

Charakterystyka produktu

ENALAPRIL
_ _
_ _
_ _
COMPOSITION
_PHARMANIAGA ENALAPRIL TABLET 5 MG _
Each tablet contains Enalapril maleate 5 mg.
_PHARMANIAGA ENALAPRIL TABLET 20 MG _
Each tablet contains Enalapril maleate 20 mg.
ACTIONS
Enalapril after hydrolysis to enalaprilat, inhibits angiotensin-
converting enzyme (ACE) in human subjects and animals.
ACE is a peptidyl dipeptidase that catalyses the conversion of
angiotensin I to the vasoconstrictor substance, angiotensin ll.
Angiotensin II also stimulates aldosterone secretion by the
adrenal
cortex.
The
beneficial
effects
of
enalapril
in
hypertension and heart failure appear to result primarily from
suppression
of
the
renin-angiotensin-aldosterone
system.
Inhibition of ACE results in decreased plasma angiotensin ll,
which
leads
to
decreased
vasopressor
activity
and
to
decreased aldosterone secretion.
While the mechanism through which enalapril lowers blood
pressure is believed to be primarily suppression of the renin-
angiotensin-aldosterone system, enalapril is antihypertensive
even in patients with low-renin hypertension.
Following oral administration of enalapril maleate peak serum
concentrations of enalapril occur within about one hour. Based
on urinary recovery, the extent of absorption of enalapril is
approximately 60%. Enalapril absorption is not influenced by
the presence of food in the gastrointestinal tract. Following
absorption, enalapril is hydrolysed to enalaprilat, which is a
more
potent
angiotensin
converting
enzyme
inhibitor
than
enalapril; enalaprilat is poorly absorbed when administered
orally.
Peak serum concentrations of enalaprilat occur three to four
hours after an oral dose of enalaprilat maleate. Excretion of
enalapril maleate is primarily renal. Approximately 94% of the
dose is recovered in the urine and faeces as enalaprilat or
enalapril. The principal components in urine are enalaprilat,
accounting for about 40% of the dose, and intact enalapril.
There is no evidence of metabolites of enalapril, other than
enalaprilat. Enalaprilat is 50 to 60% bound to plasma p